SARS-CoV-2 disrupts clinical research: the role of a rare disease-specific trial network

Silke van Koningsbruggen-Rietschel, Fiona Dunlevy, Veerle Bulteel, Damian G. Downey, Lieven Dupont

Source: Eur Respir J, 56 (3) 2002114; 10.1183/13993003.02114-2020
Journal Issue: September

Congress or journal article abstractFull text journal articlePDF journal article, handout or slides

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Silke van Koningsbruggen-Rietschel, Fiona Dunlevy, Veerle Bulteel, Damian G. Downey, Lieven Dupont. SARS-CoV-2 disrupts clinical research: the role of a rare disease-specific trial network. Eur Respir J, 56 (3) 2002114; 10.1183/13993003.02114-2020

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
How to accelerate bringing new drugs to patients: role of clinical trials networks
Source: International Congress 2019 – Rare lung diseases
Year: 2019


Key role of patients in clinical trials
Source: Research Seminar 2013 - ERS Presidential Summit on Research gaps, patient needs and innovative solutions: a forward look on lung health research
Year: 2013

Establishing new treatments: the role of RCTs
Source: Virtual Congress 2020 – Tuberculosis: learning from the WHO global health emergencies
Year: 2020


New clinical research strategies in thoracic oncology: clinical trial design, adaptive, basket and umbrella trials, new end-points and new evaluations of response
Source: Eur Respir Rev 2014; 23: 367-378
Year: 2014



The impact of embedding trial recruitment into a clinical care pathway
Source: Virtual Congress 2021 – Acute non-invasive respiratory therapies in COVID-19 and beyond
Year: 2021


Patient-ventilator interaction: assessment and clinical relevance
Source: Respiratory Failure and Mechanical Ventilation Conference 2020
Year: 2020


A critical evaluation of the relevance of different asthma phenotypes for clinical practice
Source: Annual Congress 2008 - A step-change in asthma. The Lancet/ERS symposium
Year: 2008


Evaluation of factors to consider prior to adjustment of biologic quality control ranges using data from a large multi-centre clinical trial
Source: Annual Congress 2009 - Quality control in lung function and new developments
Year: 2009


The disease model: implications for clinical practice
Source: Eur Respir J, 51 (4) 1800188; 10.1183/13993003.00188-2018
Year: 2018



A systematic review to assess the components of clinical decision support systems (CDSS) in chronic respiratory disease (CRD) and their relevance to physiotherapy management
Source: Virtual Congress 2021 – Digital health interventions in respiratory medicine
Year: 2021


Do marker states improve measurement properties of utility instruments: a randomized multi-center trial in patients with chronic respiratory disease
Source: Eur Respir J 2004; 24: Suppl. 48, 295s
Year: 2004

Impact of FVC/SVC relationship and TLC/VA relationship on biologic quality control CV in a large multi-centre clinical trial
Source: Annual Congress 2009 - Quality control in lung function and new developments
Year: 2009


The way forward: how to link real-life situations and clinical trial results
Source: Annual Congress 2013 - Lunchtime Session "Tiotropium soft mist inhaler and mortality in COPD: results of the TIOSPIR clinical trial"
Year: 2013

The impact of a new recruitment strategy to improve recruitment of participants to research studies
Source: International Congress 2019 – How to guide patients to reach a balance between costs and personal needs: quality indicators of effectiveness
Year: 2019


COPD integrated disease management, from controlled trial to real-world primary care; a cohort study.
Source: Virtual Congress 2020 – Organising respiratory disease management in primary care
Year: 2020


Cluster randomised controlled trial of the effect of introduction of an acute wheeze/asthma integrated care pathway on patient outcome
Source: Eur Respir J 2006; 28: Suppl. 50, 481s
Year: 2006

The future of translational lung cancer research: from classical randomised controlled trials to innovative platform trials
Source: International Congress 2018 – New drugs, strategies and research designs for advanced non-small cell lung cancer
Year: 2018


Clinical use of new and repurposed drugs: the role and contribution of the ERS collaborative projects
Source: International Congress 2017 – In the frontline of the fight against tuberculosis
Year: 2017